HCW Biologics Inc.
HCWB
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.0M
$1.69
▼ -1.17%
P/E
—
Mkt Cap
$1.0M
52-Wk Range
$1.50–$29.28
52-Week Range
$1.50 - $29.28
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 93.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel immunotherapy platform targeting chronic inflammation
- Diversified product pipeline across multiple therapeutic areas
- Cell-based therapy expertise with Phase II clinical data
- Proprietary approach to age-related disease treatment
Bear Case
1 risk
- High volatility (beta 2.4). Larger-than-normal price swings expected.
Growth
Stable outlook
Advancement of HCW9218 through clinical development for multiple cancer indications
Value
Valuation data unavailable
Momentum
Falling
-63.6% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying HCWB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 14, 2026
Reported EPS of -$11.58 vs -$1.98 consensus (-484.9% surprise). Revenue of $135.6K vs $135.6K expected (0.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-484.9%
Revenue trend · last 8Q
—
—
-100%
-99%
-96%
-93%
+129081%
+1970%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$426.4K
$394.8K
$5.1K
$6.5K
$15.6K
$27.0K
$6.5M
$135.6K
Margins · last 8Q
Gross
-69.3%
Profit
-11340.3%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Maxim Group · May 28, 2026
vs Industry
How HCWB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related